Skip to main content
  • Editorial: The Emperor's New Clothes: Dispelling the Myth of Improved Safety With Bare Metal

    In this issue of CRM , Gallone et al. present data from propensity-matched cohorts extracted from three registries to examine the benefit, if any, of the polymer-free biolimus-eluting stent (BioFreedom; PF-BES) as compared to the biostable-polymer zotarolimus-eluting stent (ZES) Resolute in the treatment of coronary bifurcation lesions [  ]. The primary endpoint for the study was a comparison of the major adverse cardiac events (MACE) at 400 days' follow-up between the two propensity-matched groups. As usual, even with propensity matching, one must be cautious in interpreting these data given the non-randomized and retrospective nature of this study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details